Mechanisms of hormonal therapy resistance in breast cancer

International Journal of Clinical Oncology

Volumn 20, Issue 2, 2015, Pages 262-267

  Hayashi, Shin ichi ^a   Kimura, Mariko ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen; Aromatase inhibitor; Estrogen receptor; Hormonal therapy; mTOR

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; LIGAND;

BREAST NEOPLASMS; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIGANDS; PHOSPHORYLATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84939960747     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0788-5     Document Type: Review

References (27)

1. Strasser-Weippl K, Goss PE (2005) Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23(8):1751–1759
2. Riggins RB, Schrecengost RS, Guerrero MS et al (2007) Pathways to tamoxifen resistance. Cancer Lett 256(1):1–24
3. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810
4. Yue W, Wang JP, Conaway MR et al (2003) Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 86(3–5):265–274
5. Sabnis GJ, Jelovac D, Long B et al (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65(9):3903–3910
6. Martin LA, Farmer I, Johnston SR et al (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75–S84
7. Santen RJ, Song RX, Masamura S et al (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hyper sensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19–34
8. Gohno T, Seino Y, Hanamura T et al (2012) Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance. Cancer Med 1(3):328–337
9. Yamaguchi Y, Takei H, Suemasu K et al (2005) Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res 65(11):4653–4662
10. Matsumoto M, Yamaguchi Y, Seino Y et al (2008) Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer 15(2):451–463
11. Hanamura T, Niwa T, Nishikawa S et al (2013) Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Res Treat 139(3):731–740
12. Hanamura T, Niwa T, Gohno T et al (2014) Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Breast Cancer Res Treat 143(1):69–80
13. Fujiki N, Konnno H, Kaneko Y et al (2014) Estrogen response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms. J Steroid Biochem Mol Biol 139:61–72
14. Cambell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817–9824
15. Castano E, Vorojeikina DP, Notides AC (1997) Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem J 326(Pt1):149–157
16. Yamashita H, Nishio M, Kobayashi S et al (2005) Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cacer. Breast Cancer Res 7(5):R753–R764
17. Fujii R, Hanamura T, Suzuki T et al (2014) Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol 144 Pt B:513–522
18. Miller TW (2013) Endocrine resistance: what do we know? Am Soc Clin Oncol Educ Book. doi:10.1200/EdBook_AM.2013.33.e37
19. Di Leo A, Jerusalem G, Petruzelka L et al (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337
20. Zardavas D, Phillips WA, Loi S (2014) PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 16:201
21. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529
22. Piccart M, Hortobagyi GN, Campone M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast caner: overall survival results from BOLERO-2. Ann Oncol 25:2357–2362
23. Diaby V, Adunlin G, Ali AA et al (2014) Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat 146:669–673
24. Zardavas D, Baselga J, Piccart M (2013) Emerging targeted agents in metastatic breaset cancer. Nat Rev Clin Oncol 10:191–210
25. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(631):6–43
26. Cadoo KA, Gucalp A, Traina TA (2014) Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 6:123–133
27. Johnston SR, Schiavon G (2013) Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents. Am Soc Clin Oncol Educ Book. doi:10.1200/EdBook_AM.2013.33.e28